Natera shared a post on LinkedIn:
“During our symposium at this year’s ISHLT – International Society for Heart and Lung Transplantation annual meeting, we highlighted how donor-derived cell-free DNA (dd-cfDNA) not only rules out rejection with high confidence but also detects broader allograft injury.
Experts discussed emerging data on elevated molecular injury, which is strongly linked to poor outcomes, including increased risk of chronic lung allograft dysfunction.
Watch the recording of this presentation here.”
Other articles about Natera on OncoDaily.